BACKGROUND: Understanding of immune mechanisms underpinning asthma has emerged from studies in adults. It is increasingly recognised, both immunologically and in the development of novel therapies, that adult responses cannot be used accurately to predict those of children. METHODS: Using a well-defined paediatric cohort of severe therapy-resistant asthma (STRA) patients, we investigated cytokine profiles in the airway by analysis of bronchoalveolar lavage fluid. The in vitro capacity of peripheral blood mononuclear cells (PBMCs) for cytokine production was also assessed following polyclonal T cell activation in culture, in the absence or presence of dexamethasone and 1α,25-dihydroxyvitamin D3. RESULTS: Children with both moderate and STRA had significantly diminished levels of anti-inflammatory interleukin (IL)-10 in airway lavage samples when compared with non-asthmatic controls (p<0.001). Their PBMCs also demonstrated significantly impaired capacity to secrete IL-10 in culture (p<0.001). Dexamethasone regulated the balance between PBMC IL-10 and IL-13 production, increasing IL-10 secretion (p<0.001) and decreasing IL-13 (p<0.001) but unexpectedly enhanced IL-17A production in all groups-most strikingly in the STRA cohort (p<0.001). The inclusion of the active form of vitamin D, 1α,25-dihydroxyvitamin D3, in culture enhanced dexamethasone-induced IL-10 (p<0.05) without marked effects on IL-13 or IL-17A production. Furthermore, systemic vitamin D status directly correlated with airway IL-10 (r=0.6, p<0.01). CONCLUSIONS: These findings demonstrate reduced peripheral and local IL-10 synthesis in paediatric asthma, and support therapeutic augmentation of low circulating vitamin D in severe, difficult-to-treat asthma, in order to correct impaired IL-10 levels. Conversely, steroids enhanced IL-17A levels, and therefore any steroid-sparing properties of vitamin D may have additional benefit in STRA. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
BACKGROUND: Understanding of immune mechanisms underpinning asthma has emerged from studies in adults. It is increasingly recognised, both immunologically and in the development of novel therapies, that adult responses cannot be used accurately to predict those of children. METHODS: Using a well-defined paediatric cohort of severe therapy-resistant asthma (STRA) patients, we investigated cytokine profiles in the airway by analysis of bronchoalveolar lavage fluid. The in vitro capacity of peripheral blood mononuclear cells (PBMCs) for cytokine production was also assessed following polyclonal T cell activation in culture, in the absence or presence of dexamethasone and 1α,25-dihydroxyvitamin D3. RESULTS: Children with both moderate and STRA had significantly diminished levels of anti-inflammatory interleukin (IL)-10 in airway lavage samples when compared with non-asthmatic controls (p<0.001). Their PBMCs also demonstrated significantly impaired capacity to secrete IL-10 in culture (p<0.001). Dexamethasone regulated the balance between PBMC IL-10 and IL-13 production, increasing IL-10 secretion (p<0.001) and decreasing IL-13 (p<0.001) but unexpectedly enhanced IL-17A production in all groups-most strikingly in the STRA cohort (p<0.001). The inclusion of the active form of vitamin D, 1α,25-dihydroxyvitamin D3, in culture enhanced dexamethasone-induced IL-10 (p<0.05) without marked effects on IL-13 or IL-17A production. Furthermore, systemic vitamin D status directly correlated with airway IL-10 (r=0.6, p<0.01). CONCLUSIONS: These findings demonstrate reduced peripheral and local IL-10 synthesis in paediatric asthma, and support therapeutic augmentation of low circulating vitamin D in severe, difficult-to-treat asthma, in order to correct impaired IL-10 levels. Conversely, steroids enhanced IL-17A levels, and therefore any steroid-sparing properties of vitamin D may have additional benefit in STRA. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Giuseppe Saggese; Francesco Vierucci; Flavia Prodam; Fabio Cardinale; Irene Cetin; Elena Chiappini; Gian Luigi De' Angelis; Maddalena Massari; Emanuele Miraglia Del Giudice; Michele Miraglia Del Giudice; Diego Peroni; Luigi Terracciano; Rino Agostiniani; Domenico Careddu; Daniele Giovanni Ghiglioni; Gianni Bona; Giuseppe Di Mauro; Giovanni Corsello Journal: Ital J Pediatr Date: 2018-05-08 Impact factor: 2.638
Authors: Sonali Bose; Gregory B Diette; Han Woo; Kirsten Koehler; Karina Romero; Ana M Rule; Barbara Detrick; Emily Brigham; Meredith C McCormack; Nadia N Hansel Journal: J Allergy Clin Immunol Pract Date: 2019-02-11
Authors: Brandy Reid; Pierre-Olivier Girodet; Jonathan S Boomer; Azza Abdel-Gadir; Kathy Zheng; Michael E Wechsler; Leonard B Bacharier; Susan J Kunselman; Tonya S King; Elliot Israel; Mario Castro; Manuela Cernadas; Jonathan M Green Journal: J Allergy Clin Immunol Date: 2016-02-10 Impact factor: 10.793
Authors: W Gerald Teague; Monica G Lawrence; Debbie-Ann T Shirley; Andrea S Garrod; Stephen V Early; Jackie B Payne; Julia A Wisniewski; Peter W Heymann; James J Daniero; John W Steinke; Deborah K Froh; Thomas J Braciale; Michael Ellwood; Drew Harris; Larry Borish Journal: J Allergy Clin Immunol Pract Date: 2019-01-14
Authors: Anne M Fitzpatrick; Susan T Stephenson; Milton R Brown; Khristopher Nguyen; Shaneka Douglas; Lou Ann S Brown Journal: J Allergy Clin Immunol Pract Date: 2016-09-21
Authors: Edward Zoratti; Suzanne Havstad; Ganesa Wegienka; Charlotte Nicholas; Kevin R Bobbitt; Kimberley J Woodcroft; Dennis R Ownby; Christine Cole Johnson Journal: Ann Allergy Asthma Immunol Date: 2014-05-05 Impact factor: 6.347
Authors: Elizabeth H Mann; Tzer-Ren Ho; Paul E Pfeffer; Nick C Matthews; Elfy Chevretton; Ian Mudway; Frank J Kelly; Catherine M Hawrylowicz Journal: Am J Respir Cell Mol Biol Date: 2017-09 Impact factor: 6.914
Authors: Patrick J McCullough; William P McCullough; Douglas Lehrer; Jeffrey B Travers; Steven J Repas Journal: Nutrients Date: 2021-04-29 Impact factor: 5.717